Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2391-2400

  Wu, Ying Jen Jeffrey ^a   Neuwelt, Alexander J ^a   Muldoon, Leslie L ^a   Neuwelt, Edward A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Acetaminophen; Chemo enhancement; Cisplatin; Glutathione; Ovarian cancer; SKOV3 cells

Indexed keywords

CISPLATIN; GLUTATHIONE; PACLITAXEL; PARACETAMOL; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; NFE2L2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RAT; TISSUE LEVEL; TUMOR RECURRENCE; ANIMAL; CANCER TRANSPLANTATION; CHEMO-ENHANCEMENT; DRUG SCREENING; METABOLISM; NUDE RAT; OVARY CANCER; OVARY TUMOR; SKOV3 CELLS; TUMOR CELL LINE;

ACETAMINOPHEN; CHEMO-ENHANCEMENT; CISPLATIN; GLUTATHIONE; OVARIAN CANCER; SKOV3 CELLS;

ACETAMINOPHEN; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; FEMALE; GLUTATHIONE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASM TRANSPLANTATION; NF-E2-RELATED FACTOR 2; OVARIAN NEOPLASMS; PACLITAXEL; RATS; RATS, NUDE; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84881362535     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bookman MA: First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol 55: 96-113, 2012.
2. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T and Lopes C: Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione-S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8: 156-161, 2003.
3. Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
4. Fracasso PM: Overcoming drug resistance in ovarian carcinoma. Curr Oncol Rep 3: 19-26, 2001.
5. Zhang K, Chew M, Yang EB, Wong KP and Mack P: Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 59: 837-843, 2001.
6. Horwitz SB: Taxol (paclitaxel): Mechanisms of action. Ann Oncol 5(Suppl 6): S3-6, 1994.
7. Ahn HJ, Kim YS, Kim JU, Han SM, Shin JW and Yang HO: Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J Cell Biochem 91: 1043-1052, 2004.
8. Wang Q, Zheng XL, Yang L, Shi F, Gao LB, Zhong YJ, Sun H, He F, Lin Y and Wang X: Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J Exp Clin Cancer Res 29: 159-166, 2010.
9. Johnson SW, Ozols RF and Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71: 644-649, 1993.
10. Sprem M, Babic D, Abramic M, Vrhovec I, Skrk J, Milicic D, Ambriovic Ristov A, Kalafatic D and Osmak M: Glutathione and glutathione-S-transferases as early markers for ovarian carcinomas: Case series. Croat Med J 42: 624-629, 2001.
11. Nakagawa K, Yokota J, Wada M, Sasaki Y, Fujiwara Y, Sakai M, Muramatsu M, Terasaki T, Tsunokawa Y, Terada M and Saijo N: Levels of glutathione-S- transferase π mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J Cancer Res 79: 301-304, 1988.
12. Manov I, Hirsh M and Iancu TC: N-Acetylcysteine does not protect HepG2 cells against acetaminophen-induced apoptosis. Basic Clin Pharmacol Toxicol 94: 213-225, 2004.
13. Wan J, Bae MA and Song BJ: Acetoaminophen-induced accumulation of 8-oxodeoxyguanosine through reduction of OGG1 DNA repair enzyme in C6 glioma cells. Exp Mol Med 36: 71-77, 2004.
14. Jaeschke H and Bajt ML: Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 89: 31-41, 2006.
15. Posadas I, Vellecco V, Santos P, Prieto-Lloret J and Cena V: Acetaminophen potentiates staurosporine-induced death in a human neuroblastoma cell line. Br J Pharmacol 150: 577-585, 2007.
16. Estabrook RW: A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab Dispos 31: 1461-1473, 2003.
17. Kon K, Ikejima K, Okumura K, Aoyama T, Arai K, Takei Y, Lemasters JJ and Sato N: Role of apoptosis in acetaminophen hepatotoxicity. J Gastroenterol Hepatol 22(Suppl 1): S49-52, 2007.
18. Bilir A, Altinoz MA, Attar E, Erkan M and Aydiner A: Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro. Neoplasma 49: 38-42, 2002.
19. Neuwelt AJ, Wu YJ, Knap N, Losin M, Neuwelt EA, Pagel MA, Warmann S, Fuchs J, Czauderna P and Wozniak M: Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia 11: 1003-1011, 2009.
20. Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C and Chapman PB: Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 13: 189-196, 2003.
21. Kobrinsky NL, Hartfield D, Horner H, Maksymiuk A, Minuk GY, White DF and Feldstein TJ: Treatment of advanced malignancies with high-dose acetaminophen and Nacetylcysteine rescue. Cancer Invest 14: 202-210, 1996.
22. Kobrinsky NL, Sjolander DE, Goldenberg JA and Ortmeier TC: Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-Acetylcysteine rescue. Pediatr Blood Cancer 45: 222-225, 2005.
23. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE and Grizzle WE: Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8: 202-209, 2002.
24. Bishop GM, Dringen R and Robinson SR: Zinc stimulates the production of toxic reactive oxygen species (ROS) and inhibits glutathione reductase in astrocytes. Free Radic Biol Med 42: 1222-1230, 2007.
25. Wu YJ, Muldoon LL and Neuwelt EA: The chemoprotective agent N-Acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312: 424-431, 2005.
26. Reers M, Smith TW and Chen LB: J-Aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30: 4480-4486, 1991.
27. Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG and Neuwelt EA: Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia 11: 187-195, 2009.
28. Gosland M, Lum B, Schimmelpfennig J, Baker J and Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39, 1996.
29. Estrela JM, Ortega A and Obrador E: Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43: 143-181, 2006.
30. Fath MA, Ahmad IM, Smith CJ, Spence J and Spitz DR: Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res 17: 6206-6217, 2011.
31. Runowicz CD, Fields AL and Goldberg GL: Promising new therapies in the treatment of advanced ovarian cancer. Cancer 76: 2028-2033, 1995.
32. Macanas-Pirard P, Yaacob NS, Lee PC, Holder JC, Hinton RH and Kass GE: Glycogen synthase kinase-3 mediates acetaminophen-induced apoptosis in human hepatoma cells. J Pharmacol Exp Ther 313: 780-789, 2005.
33. Manov I, Bashenko Y, Hirsh M and Iancu TC: Involvement of the multidrug resistance P-glycoprotein in acetaminopheninduced toxicity in hepatoma-derived HepG2 and Hep3B cells. Basic Clin Pharmacol Toxicol 99: 213-224, 2006.
34. Casper D, Lekhraj R, Yaparpalvi US, Pidel A, Jaggernauth WA, Werner P, Tribius S, Rowe JD and LaSala PA: Acetaminophen selectively reduces glioma cell growth and increases radiosensitivity in culture. J Neurooncol 46: 215-229, 2000.
35. Bae MA, Pie JE and Song BJ: Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH(2)-terminal protein kinase-related cell death pathway. Mol Pharmacol 60: 847-856, 2001.
36. Harnagea-Theophilus E, Gadd SL, Knight-Trent AH, DeGeorge GL and Miller MR: Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors. Toxicol Appl Pharmacol 155: 273-279, 1999.
37. Gadd SL, Hobbs G and Miller MR: Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-MYC RNA expression and NF-KB activity. Toxicol Sci 66: 233-243, 2002.
38. Kostrubsky VE, Lewis LD, Wood SG, Sinclair PR, Wrighton SA and Sinclair JF: Effect of Taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: comparison to dexamethasone. Toxicol Appl Pharmacol 142: 79-86, 1997.
39. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A and Safa AR: Taxol induces caspase-10-dependent apoptosis. J Biol Chem 279: 51057-51067, 2004.
40. Chia AJ, Goldring CE, Kitteringham NR, Wong SQ, Morgan P, and Park BK: Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of NRF2 and NF-KB. Biochem Pharmacol 80: 410-421, 2010.
41. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W and Zhang DD: High levels of NRF2 determine chemoresistance in type II endometrial cancer. Cancer Res 70: 5486-5496, 2010.
42. Copple IM, Goldring CE, Jenkins RE, Chia AJ, Randle LE, Hayes JD, Kitteringham NR and Park BK: The hepatotoxic metabolite of acetaminophen directly activates the KEAP1-NRF2 cell defense system. Hepatology 48: 1292-1301, 2008.
43. Perez MJ, Gonzalez-Sanchez E, Gonzalez-Loyola A, Gonzalez-Buitrago JM and Marin JJ: Mitochondrial genome depletion dysregulates bile acid-And paracetamol-induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells. Br J Pharmacol 162: 1686-1699, 2011.
44. Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ and Mulder GJ: Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells. Biochem Pharmacol 58: 655-664, 1999.
45. Shaw TJ, Senterman MK, Dawson K, Crane CA and Vanderhyden BC: Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032-1042, 2004.
46. Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, Egorin MJ and Neuwelt EA: Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 6: 309-315, 2000.
47. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR and Muldoon LL: Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309: 594-599, 2004.
48. Jemnitz K, Veres Z, Monostory K, Kobori L and Vereczkey L: Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes. Toxicol In Vitro 22: 961-967, 2008.
49. Akai S, Hosomi H, Minami K, Tsuneyama K, Katoh M, Nakajima M and Yokoi T: Knock down of gammaglutamylcysteine synthetase in rat causes acetaminopheninduced hepatotoxicity. J Biol Chem 282: 23996-24003, 2007.
50. Neuwelt AJ, Nguyen T, Wu YJ, Donson AM, Vibhakar R, Venkatamaran S, Amani V, Neuwelt EA, Rapkin LB and Foreman NK: Preclinical high-dose acetaminophen with Nacetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors. Pediatr Blood Cancer (in press), 2013.